The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 19, 2014

Filed:

Apr. 01, 2011
Applicants:

Adrian Bot, Beverly Hills, CA (US);

Lilin Wang, San Diego, CA (US);

Dan Joseph Smith, San Diego, CA (US);

William Joseph Phillips, Jr., San Diego, CA (US);

Luis A. Dellamary, San Marcos, CA (US);

Inventors:

Adrian Bot, Beverly Hills, CA (US);

Lilin Wang, San Diego, CA (US);

Dan Joseph Smith, San Diego, CA (US);

William Joseph Phillips, Jr., San Diego, CA (US);

Luis A. Dellamary, San Marcos, CA (US);

Assignee:

Multicell Immunotherapeutics, Inc., Woonsocket, RI (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/117 (2010.01); A61K 39/12 (2006.01); A61K 38/02 (2006.01); A61K 31/713 (2006.01); A61K 39/145 (2006.01); A61K 39/39 (2006.01); A61K 31/7105 (2006.01); A61K 45/06 (2006.01); A61K 39/21 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7105 (2013.01); A61K 31/713 (2013.01); A61K 39/145 (2013.01); C12N 2740/16034 (2013.01); A61K 2039/55561 (2013.01); A61K 39/0011 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/53 (2013.01); A61K 2039/5252 (2013.01); A61K 39/39 (2013.01); A61K 2039/57 (2013.01); A61K 45/06 (2013.01); C12N 2710/20034 (2013.01); A61K 2039/544 (2013.01); A61K 39/12 (2013.01); A61K 39/21 (2013.01); C12N 2760/16134 (2013.01);
Abstract

The present invention is directed to novel compositions that cause effective redirection of class I-immunity to Tc1 effectors, that take advantage of the unexpected loading of MHC I by peptide within IgG backbone combined with appropriate instruction of antigen presenting cells. Such compositions are able to transform a seemingly ineffective therapeutics into a highly effective one, associated with generation of class I-restricted cytolytic cells and IFN-γ, IL-2 producing T cells, further associated with protection against a highly virulent microbe or recovery from malignant tumoral process.


Find Patent Forward Citations

Loading…